Assay development & optimisation

Scientist Loads Samples Into Mercury
#AI / data analytics / healthtech / informatics #Arrayjet #Assay development & optimisation #Chemspace #Collaboration #High throughput screening

Arrayjet announces collaboration with Chemspace

Arrayjet and Chemspace have agreed a partnership to augment and streamline Chemspace’s small molecule microarray (SMM) service offering. Chemspace’s compound libraries are now accessible through Arrayjet’s SMM CRO/CMO services for assay development, contract screening and contract array manufacturing. SMMs enable high-throughput screening of compound… Read More

#News

#Assay development & optimisation #Biomarkers #Plasma proteome

How to identify actionable biomarkers from the plasma proteome

In a study published in Neurology, a group from Alnylam Pharmaceuticals used large-scale protein screening assays to simultaneously analyse many proteins in vast numbers of patient serum samples. This approach allowed them to discover a novel biomarker of hereditary transthyretin-mediated (ATTRv) amyloidosis disease onset and progression. ATTRv amyloidosis, caused by mutation… Read More

#Editor's Choice #News

#Assay #Assay development & optimisation #Drug discovery

BioIVT to supply PBMCs for new bioassay

BioIVT, provider of research models and services for drug and diagnostic development, is supplying peripheral blood mononuclear cells (PBMCs) for Promega’s antibody-dependent Cellular Cytotoxicity (ADCC) bioassay bioassay, which uses PBMCs to mimic in vivo conditions and measure the ADCC of antibodies during drug development and characterisation. “This new platform combines BioIVT’s high… Read More

#News

#Assay development & optimisation #Drug discovery #Therapeutics

PerkinElmer launches assay kits to help advance therapeutics discovery

PerkinElmer has announced the addition of new assay kits to help further GPCR (G Protein-Coupled Receptor) therapeutic discovery. The new offerings extend the company’s GPCR analysis portfolio, which includes assays, plate readers, automation technologies and software solutions combined with siRNA, shRNA, CRISPR, and cDNA/ORF libraries to help scientists more easily… Read More

#News

#Antibodies #Assay development & optimisation #Bispecific therapeutics

Fast way to screen bispecific antibodies using protein A and His1K biosensors

Recent biotechnological advances have fuelled development bispecific antibodies (bsAbs) in the last 10 years. However, the functional analysis of bsAbs during bioprocessing adds a challenge for scientists given the array of bsAbs populated by many different species, comprising many different formats, and that traditional SPR and ELISA methods for bsAbs… Read More

#News

#Assay development & optimisation #Immunology / Virology & Vaccines

Nexelis aquires GSK Vaccines’ German clinical bioanalytical lab

Nexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields, has signed an asset purchase agreement with GSK to acquire its GCLP-certified clinical bioanalytical laboratory located in Marburg, Germany. The Clinical Laboratory… Read More

#News

#Assay development & optimisation #Drug discovery #In vitro

Eurofins, a focus on drug discovery expertise

Eurofins Discovery is a CRO with a range of expertise in drug discovery. Christina Shasserre, Senior VP spoke to Lu Rahman about some of the company’s current COVID-related work as well as offering insight into the drug discovery landscape.   LR: Are you able to share some of Eurofins Discovery’s… Read More

#News #Opinion

#Assay development & optimisation #Drug discovery

Accelerating assay development optimisation for drug discovery

Dr. Zack Gurard-Levin, Chief Scientific Officer, SAMDI Tech offers five challenges and solutions for optimal assay development in drug discovery Developing a suitable assay is critical to identifying and characterising novel drug leads. While designing an assay may appear straightforward, developing the assay in an optimised format for a particular… Read More

#Exclusive Content

#Assay development & optimisation #Drug discovery

Event for assay developers, screening scientists and drug discovery research scientists

We understand the importance of kinetic assay design. In the upcoming DDW collaboration, supported by SPT Labtech, Dr Nick Holliday, Chief Scientific Officer, Excellerate Bioscience, will share his pharmacology expertise to explain how to produce assays that deliver hits with higher physiological relevance. Due to popularity we have opened up… Read More

#Editor's Choice #News

#Assay development & optimisation #Drug discovery

Industry insight on designing assays that deliver hits with higher physiological relevance

DDW is delighted to announce an exclusive event, supported by SPT Labtech, that will allow you to gain knowledge on kinetic assay design and take this forward to produce assays that deliver hits with higher physiological relevance. Pharmacology expert Dr Nick Holliday, chief scientific officer, Excellerate Bioscience, will lead this… Read More

#Editor's Choice #News

#Assay development & optimisation #Drug discovery

Pharmacology expert explains how to improve the drug discovery process

In an exclusive event for DDW, Dr Holliday, Chief Scientific Officer, Excellerate Bioscience, will focus on the importance of kinetic assays in drug discovery. What you will learn: How association and dissociation rate constants describe compound binding kinetics The potential clinical benefits of optimising kinetic constants when compound profiling The… Read More

#News

#Assay development & optimisation #Drug discovery

Putting the dynamics into compound profiling: using kinetic assays to shape early stage drug discovery

In vitro early stage compound profiling often focusses on single timepoint measurements of drug action, for example the affinity of the drug for its target at equilibrium, or the endpoint response in a signalling assay. However, in vivo, drug action occurs within a highly dynamic system. Drug and competing messenger… Read More

Webinar date:
Brought to you by SPT Labtech
#Webinars

#Assay development & optimisation

PROTAC assays: successfully measuring protein degradation

PROTAC (PROteolysis TArgeting Chimera) is one of the hottest topics in drug discovery today as it is a highly promising new approach to targeted therapy. It offers several advantages over traditional occupancy-based drugs, with a potential to target the ‘undruggable’ proteome. Payash Bahuguna, Aurelia Bioscience explains more about PROTAC and… Read More

#News

#Assay development & optimisation #Biomarkers #Diagnostics #In vitro

BioIVT to host emerging technologies in diagnostics symposium

BioIVT will be hosting a virtual Emerging Technologies in Diagnostics Symposium on  Thursday, October 29 (10am-1pm ET). “The diagnostic assay landscape is changing rapidly as the demand for faster, less expensive, more precise diagnostics continues to grow,” said Cathie Miller, Director of Product Marketing, Personalised Medicine at BioIVT. “We wanted… Read More

#News

#Adeptrix #Assay development & optimisation #Avacta #Covid-19

Avacta launches BAMS assay to detect SARS-CoV-2 research test

Avacta’s BAMS assay to detect the SARS-CoV-2 virus has been launched as a research kit by its partner Adeptrix and the assay has been presented by Bruker Scientific, a mass spectrometer manufacturer, in a new application note. The bead-assisted mass spectrometry (BAMS) assay uses the Affimer reagents specific to the… Read More

#Covid-19 #News